A canine model of heart failure by intracoronary Adriamycin injection: Hemodynamic and energetic results

Journal of Cardiac Failure

Volumn 5, Issue 3, 1999, Pages 255-264

  Monnet, Eric ^a   Orton, E Christopher ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

Animal; Cardiac efficiency; Cardiomyopathy; Histology

Indexed keywords

ANIMAL EXPERIMENT; ARTICLE; CONGESTIVE CARDIOMYOPATHY; DOG; HEART CATHETERIZATION; HEART FAILURE; HEART HEMODYNAMICS; NONHUMAN; PRIORITY JOURNAL;

EID: 0032862928     PISSN: 10719164     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1071-9164(99)90010-6     Document Type: Article

References (45)

1. Smith HJ, Nuttall A: Experimental models of heart failure. Cardiovasc Res 1985;19:181-6
2. Williams GJ, Elston J, Muir JR: A simplified technique for the production of experimental aortic regurgitation. Cardiovasc Res 1975;9:440-2
3. Rogers WA, Bishop SP, Hamlin R: Experimental production of supravalvular aortic stenosis in the dog. J Appl Physiol 1971;30:917-20
4. Dell'italia LJ, Blackwell GG, Urthaler F, Pearce DJ, Pohost GM: A stable model of left ventricular dysfunction in an intact animal assessed with high fidelity pressure and cinemagnetic resonance imaging. Cardiovasc Res 1993;27: 974-9
5. Garcia R, Diebold S: Simple, rapid, and effective method of producing aortocaval shunts in the rat. Cardiovasc Res 1990;24:430-2
6. Taylor RR, Covell JW, Ross J: Left ventricular function in experimental aorto-caval fistula with circulatory congestion and fluid retention. J Clin Invest 1968;47:1333-42
7. Kern KB, Lancaster LD, Olajos M, Goldman S: A closedchest porcine model of chronic ventricular systolic and diastolic dysfunction after myocardial infarction. Coron Artery Dis 1991;2:685-9
8. Sabbah HN, Stein PD, Kono T, Gheorghiade M, Levine TB, Jafri S, Hawkins ET, Goldstein S: A canine model of chronic heart failure produced by multiple sequential coronary microembolizations. Am J Physiol 1991;260: 1379-84
9. Millner RWJ, Mann JM, Pearson I, Pepper JR: Experimental model of left ventricular failure. Ann Thorac Surg 1991;52:78-83
10. McDonald KM, Francis GS, Carlyle PF, Hauer K, Matthews J, Hunter DW, Cohn JN: Hemodynamic, left ventricular structural and hormonal changes after discrete myocardial damage in the dog. J Am Coll Cardiol 1992; 19:460-7
11. Armstrong PW, Stopps TP, Ford SE, De Bold AJ: Rapid ventricular pacing in the dog: pathophysiologic studies of heart failure. Circulation 1986;74:1075-84
12. Li HG, Jones DL, Yee R, Klein GJ: Electrophysiologic substrate associated with pacing-induced heart failure in dogs: potential value of programmed stimulation in predicting sudden death. J Am Coll Cardiol 1992;19:444-9
13. Sparano BM, Gordon G, Iatropoulos MJ, Noble JF: Safety assessment of a new anticancer drug compound, mitoxantrone, in beagle dogs: comparison with doxorubicin. II. Histologic and ultrastructural pathology. Cancer Treat Rep 1982;66:1145-58
14. Kehoe R, Singer DH, Trapani A, Billingham M, Levandowski R, Elson J: Adriamycin-induced cardiac dysrhythmias in an experimental dog model. Cancer Treat Rep 1978;62:963-77
15. Van Vleet JF, Ferrans VJ, Weirich WE: Cardiac disease induced by chronic Adriamycin administration in dogs and an evaluation of vitamin E and selenium as cardioprotectants. Am J Pathol 1980;99:13-22
16. Unverferth DV: Anthracycline-induced heart disease. In Unverferth DV: Dilated cardiomyopathy. Futura, Mount Kisco, 1985, pp. 179-200
17. Ogilvie GK, Richardson RC, Curtis CR, Withrow SJ, Reynolds HA, Norris AM, Henderson RA, Klausner JS, Fowler JD, McCaw D: Acute and short-term toxicoses associated with the administration of doxorubicin to dogs with malignant tumors. J Am Vet Med Assoc 1989;195: 1584-7
18. Susaneck SJ: Doxorubicin therapy in the dog. J Am Vet Med Assoc 1983;182:70-2
19. Cheng W, Michele JJ, Spinale FG, Sink JD, Santamore WP: Effects of cardiomyoplasty on biventricular function in canine chronic heart failure. Ann Thorac Surg 1993;55: 893-901
20. Magovern JA, Christlieb IY, Badylak SF, Lantz GC, Kao RL: A model of left ventricular dysfunction caused by intracoronary Adriamycin. Ann Thorac Surg 1992;53: 861-3
21. Shah HR, Vaynblat M, Ramdev G, Cunningham JN Jr, Chiavarelli M: Experimental cardiomyopathy as a model of chronic heart failure. J Invest Surg 1997;10:387-96
22. Boon J, Wingfield WE, Miller CW: Echocardiographic indices in the normal dog. Vet Radiol 1983;24:214-21
23. Monnet E, Orton EC: Myocardial oxygen consumption and cardiac efficiency after dynamic cardiomyoplasty in dogs with adriamycin-induced cardiomyopathy. Arch Mal Coeur Vaiss 1998;91:71 (special III)
24. Feigenbaum H: Echocardiographic evaluation of cardiac chambers. In Feigenbaum H: Echocardiography. Lea & Febiger, Philadelphia, 1994, pp. 134-80
25. Schiller NB, Skioldebrand CG, Schiller EJ, Mavroudis CC, Silverman NH, Rahimtoola SH, Lipton MJ: Canine left ventricular mass estimation by two-dimensional echocardiography. Circulation 1983;68:210-6
26. Ganz W, Tamura K, Marcus HS, Donoso R, Yoshida S, Swan HJC: Measurement of coronary sinus blood flow by continuous thermodilution in man. Circulation 1971;154: 181-95
27. Lee ET: Statistical methods for survival data analysis (ed 2). Wiley, New York, 1992
28. Gralla EJ, Fleishman RW, Luthra YK, Stadnicki SW: The dosing schedule dependent toxicities of Adriamycin in beagle dogs and rhesus monkeys. Toxicology 1979;13: 263-73
29. Kameyama T, Asanoi H, Ishizaka S, Yamanishi K, Fujita M, Sasayama S: Energy conversion efficiency in human left ventricle. Circulation 1992;85:988-96
30. Suga H, Igarashi Y, Yamada O, Goto Y: Mechanical efficiency of the left ventricle as a function of preload, afterload, and contractility. Heart Vessels 1985;1:3-8
31. Calvert CA, Brown J: Use of M-mode echocardiography in the diagnosis of congestive cardiomyopathy in Doberman Pinschers. J Am Vet Med Assoc 1986;189:293-7
32. Stoddard MF, Seeger J, Liddell NE, Hadley TJ, Sullivan DM, Kupersmith J: Prolongation of the isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans. J Am Coll Cardiol 1992;20:62-9
33. Bristow MR, Mason JW, Billingham ME, Daniels JR: Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. Ann Intern Med 1978;88:168-75
34. Bristow MR, Mason JW, Billingham ME, Daniels JR: Dose effect and structure function relationships in doxorubicin cardiomyopathy. Am Heart J 1981;102:709-18
35. Henderson C, Sloss LJ, Jaffe N, Blum RH, Frei E: Serial studies of cardiac function in patients receiving Adriamycin. Cancer Treat Rep 1978;62:923-9
36. Billingham ME, Mason JW, Bristow MR, Daniels JR: Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep 1978;62:865-72
37. Mason JW, Bristow MR, Billingham ME, Daniels JR: Invasive and noninvasive methods of assessing Adriamycin cardiotoxic effects in man: superiority of histopathologic assessment during endomyocardial biopsy. Cancer Treat Rep 1978;62:857-64
38. Lees GE, Simpson RB, Green RA: Results of analyses and bacterial cultures of urine specimens obtained from clinically normal cats by three methods. J Am Vet Med Assoc 1984;184:449-54
39. Henderson BM, Dougherty WJ, James VC, Tilley LP, Noble JF: Safety assessment of a new anticancer compound, mitoxantrone, in beagle dogs: comparison with doxorubicin. I. Clinical observations. Cancer Treat Rep 1982;66:1139-43
40. McKillop JH, Bristow MR, Goris ML, Bockemuehl K: Sensitivity and specificity of radionucleide ejection fractions in doxorubicin cardiotoxicity. Am Heart J 1983;106: 1048-56
41. Steinherz LJ, Steinherz PG, Charlotte TC, Heller G, Murphy L: Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991;266:1672-7
42. Von Hoff DD, Layard MW, Basa P, Von Hoff AL: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710-7
43. Rabkin SW, Godin DV: Adriamycin cardiotoxicity and calcium entry blockers: the need for caution in the combination. Can J Cardiol 1985;1:IV-VII
44. Bright JM, Buss DD: Effects of verapamil on chronic doxorubicin-induced cardiotoxicity in dogs. J Natl Cancer Inst 1990;82:963-4
45. Pereira E, Borrel MN, Fiallo M, Garnier-Suillerot A: Noncompetitive inhibition of P-glycoprotein-associated efflux of THP-Adriamycin by verapamil in living K562 leukemia cells. Biochim Biophys Acta Mol Basis Dis 1994;1225: 209-16